Trials / Completed
CompletedNCT00040183
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
A Randomized Placebo Controlled Study of OSI-774 (Tarceva (TM)) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 569 (actual)
- Sponsor
- OSI Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if OSI-774 will improve overall survival when combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarceva (erlotinib HCl, OSI-774) |
Timeline
- Start date
- 2001-11-29
- Primary completion
- 2004-01-15
- Completion
- 2004-01-15
- First posted
- 2002-06-25
- Last updated
- 2018-01-10
Locations
140 sites across 17 countries: United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, Germany, Greece, Israel, Italy, Mexico, New Zealand, Poland, Romania, Singapore, United Kingdom
Source: ClinicalTrials.gov record NCT00040183. Inclusion in this directory is not an endorsement.